4579 — RaQualia Pharma Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.07 | ||
| Price to Tang. Book | 3.82 | ||
| Price to Free Cashflow | 35.5 | ||
| Price to Sales | 4.16 | ||
| EV to EBITDA | 17.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.21% | ||
| Return on Equity | 2.28% | ||
| Operating Margin | 8.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 2,776.23 | 2,918.04 | 1,901.2 | 3,107.57 | 3,979.96 | 4,587 | n/a | 29.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +0.72 | n/a | n/a | n/a | +114.68 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RaQualia Pharma Inc. is a Japan-baseddrug discovery venture company engaged in the research and development of pharmaceuticals and related businesses. It operates through a single segment: Pharmaceutical Research and Development. Leveraging cutting-edge science and technology, it aims to create novel drugs targeting disease areas with high medical needs. Research and development is conducted primarily through exploratory research, preclinical trials, and early-stage clinical trials, and the intellectual property related to the developed compounds is licensed out to pharmaceutical companies and other entities. While based on small molecule drug discovery, the Company also expands its research and development into new modality areas.
Directors
- Naoki Tani PRE (65)
- Shinichi Koizumi SME (57)
- Akihiro Furuta MEO (53)
- Kiichiro Kawada MEO
- Shuzo Watanabe EXO
- Susumu Tsuchiya DRC (63)
- Hatsuo Aoki IND (77)
- Akimitsu Hirai IND (53)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- February 19th, 2008
- Public Since
- July 20th, 2011
- No. of Shareholders
- 12,501
- No. of Employees
- 85
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 26,031,232
- Address
- 8F, Daiwa Meieki Bldg., NAGOYA-SHI, 450-0003
- Web
- https://www.raqualia.com
- Phone
- +81 524466100
- Auditors
- Ernst & Young ShinNihon LLC
Latest News for 4579
Upcoming Events for 4579
Q3 2026 RaQualia Pharma Inc Earnings Release
Dividend For 4579.T - 0.0000 JPY
Similar to 4579
ASKA Pharmaceutical Holdings
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings
Tokyo Stock Exchange
CanBas
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 22:53 UTC, shares in RaQualia Pharma are trading at ¥623. This share price information is delayed by 15 minutes.
Shares in RaQualia Pharma last closed at ¥623 and the price had moved by +15.37% over the past 365 days. In terms of relative price strength the RaQualia Pharma share price has underperformed the Nikkei 225 Index by -10.49% over the past year.
The overall consensus recommendation for RaQualia Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreRaQualia Pharma does not currently pay a dividend.
RaQualia Pharma does not currently pay a dividend.
RaQualia Pharma does not currently pay a dividend.
To buy shares in RaQualia Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥623, shares in RaQualia Pharma had a market capitalisation of ¥16bn.
Here are the trading details for RaQualia Pharma:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4579
Based on an overall assessment of its quality, value and momentum RaQualia Pharma is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in RaQualia Pharma is ¥1,200. That is 92.62% above the last closing price of ¥623.
Analysts covering RaQualia Pharma currently have a consensus Earnings Per Share (EPS) forecast of ¥48 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RaQualia Pharma. Over the past six months, its share price has underperformed the Nikkei 225 Index by -25.08%.
As of the last closing price of ¥623, shares in RaQualia Pharma were trading -12.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The RaQualia Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥623.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
RaQualia Pharma's management team is headed by:
- Naoki Tani - PRE
- Shinichi Koizumi - SME
- Akihiro Furuta - MEO
- Kiichiro Kawada - MEO
- Shuzo Watanabe - EXO
- Susumu Tsuchiya - DRC
- Hatsuo Aoki - IND
- Akimitsu Hirai - IND